Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Novel method to characterize immune cells from human prostate tissue.

Norström MM, Rådestad E, Stikvoort A, Egevad L, Bergqvist M, Henningsohn L, Mattsson J, Levitsky V, Uhlin M.

Prostate. 2014 Oct;74(14):1391-9. doi: 10.1002/pros.22854. Epub 2014 Aug 11.

PMID:
25111297
2.

Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.

Tokmadžić VS, Tomaš MI, Sotošek S, Laškarin G, Dominović M, Tulić V, Dorđević G, Sustić A, Mrakovčić-Šutić I.

Scand J Immunol. 2011 Oct;74(4):368-76. doi: 10.1111/j.1365-3083.2011.02569.x.

3.

Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Sotosek S, Sotosek Tokmadzic V, Mrakovcic-Sutic I, Tomas MI, Dominovic M, Tulic V, Sutic I, Maricic A, Sokolic J, Sustic A.

Wien Klin Wochenschr. 2011 Dec;123(23-24):718-25. doi: 10.1007/s00508-011-0096-7. Epub 2011 Nov 23.

PMID:
22105113
4.

Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.

Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE.

Lab Invest. 1992 Jan;66(1):96-107.

PMID:
1370561
5.
6.

Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.

Hussein MR, Al-Assiri M, Musalam AO.

Exp Mol Pathol. 2009 Apr;86(2):108-13. doi: 10.1016/j.yexmp.2008.11.010. Epub 2008 Dec 10.

PMID:
19111537
7.

p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.

Schlechte H, Lenk SV, Löning T, Schnorr D, Rudolph BD, Ditscherlein G, Loening SA.

Eur Urol. 1998;34(5):433-40.

PMID:
9803007
8.

Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue.

Lin VK, Wang D, Lee IL, Vasquez D, Fagelson JE, McConnell JD.

Prostate. 2000 Aug 1;44(3):193-203.

PMID:
10906735
9.

Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.

Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E.

Prostate. 2008 Jan 1;68(1):1-10.

PMID:
17948280
10.

CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.

Zambra FM, Biolchi V, Brum IS, Chies JA.

Hum Immunol. 2013 Aug;74(8):1003-8. doi: 10.1016/j.humimm.2013.04.031. Epub 2013 Apr 28.

PMID:
23632061
11.

Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.

Brössner C, Petritsch K, Fink K, Auprich M, Madersbacher S, Adlercreutz H, Rehak P, Petritsch P.

Urology. 2004 Oct;64(4):707-11.

PMID:
15491706
12.

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.

Cancer Immunol Immunother. 2008 Jan;57(1):43-52. Epub 2007 Jun 20.

13.

Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.

König JE, Senge T, Allhoff EP, König W.

Prostate. 2004 Feb 1;58(2):121-9.

PMID:
14716737
14.
15.

Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.

Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.

16.

MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma.

Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P.

Prostate. 1997 Dec 1;33(4):233-9.

PMID:
9397194
17.
19.
20.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI.

Urology. 1999 Apr;53(4):696-700.

PMID:
10197843

Supplemental Content

Support Center